Recombinant human microplasmin expressed by escherichia coli, production method of recombinant human microplasmin, pharmaceutical composition containing recombinant human microplasmin, kit containing recombinant human microplasmin, method for treating thromboembolism-related diseases by using recombinant human microplasmin, and application of recombinant human microplasmin

Through the recombinant human microplasmin expressed by E. coli, alanine scanning mutagenesis technology is used to solve the problems of low efficiency of existing thrombolytic drugs and bleeding side effects, achieving transient effective dissolution of thrombus and reducing bleeding risk.

CN119053700APending Publication Date: 2024-11-29SHENZHEN BAY LAB
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380031900.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-30
Filing Date
2023-03-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing thrombolytic drugs such as tPA and uPA have problems with inefficiency and fatal bleeding side effects in the treatment of thromboembolic, especially due to the inhibitory effect of α2-antithrombin and the proteolytic activity caused by the long in vivo half-life of the drug. It is difficult to effectively dissolve the thrombus and avoid the risk of bleeding.

Method used

Recombinant human microplasmin (E-μPlm) expressed by E. coli was used to change the surface residues of the catalytic domain by alanine scanning mutagenesis, so that it has a short half-life in vivo, can automatically activate and resist α2-anticoagulation. Inhibition of thrombin forms an unstable version of zymogen, avoids bleeding side effects, and has high catalytic activity.

Benefits of technology

The E-μPlm that exists briefly in the body can effectively dissolve thrombus, avoid bleeding side effects, and significantly reduce the inhibitory effect of α2-antithrombin, improving the safety and efficiency of thrombolytic treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053700A_ABST
    Figure CN119053700A_ABST
Patent Text Reader

Abstract

The invention provides recombinant human microplasmin (E-muPlm) expressed by escherichia coli, a production method of the recombinant human microplasmin (E-muPlm), a pharmaceutical composition and a kit containing the pharmaceutical composition. The invention also relates to applications of the pharmaceutical composition and the kit in treating thromboembolism related diseases, and a method for treating thromboembolism related diseases by using the pharmaceutical composition and the kit. The zymogen version of E-[mu] Plm or E-[mu] Plg is unstable and can be automatically activated. Furthermore, the in vivo half-life of E-[mu] Plm is significantly shorter than that of yeast-expressed microplasmin (Y-[mu] Plm), which makes the E-[mu] Plm, the pharmaceutical composition, and the kit effective in the treatment of thromboembolic diseases but reduced in bleeding side effects.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Application No. 17709403, filed on March 30, 2022, entitled “SHORT IN VIVO HALF-LIFE AND INVIVO UNSTABLE RECOMBINANT MICROPLASMIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND METHOD OF TREATING THROMBOEMBOLISM RELATED DISEASES INCLUDING ADMINISTRATION THEREOF,” the contents of which are incorporated herein by reference in their entirety. See sequence listing The sequence listing resubmitted simultaneously in accordance with the WIPOST.26 standard, with the file name core-patent2.xml, is incorporated herein by reference. The electronic copy of the sequence listing was created on March 25, 2023, and the file size is 16.0 bytes. Technical Field

[0001] The present application relates to the technical field of recombinant proteins, and more specifically to a recombinant human microplasmin expressed by Escherichia coli, a production method thereof, a pharmaceutical composition thereof, and a kit containing the same, as well as an application and method of treating thromboembolism-related diseases by using the pharmaceutical composition and the kit. Background Art

[0002] According to the American Heart Association, despite the huge impact of the COVID-19 pandemic on health, cardiovascular disease remains the leading cause of death worldwide. The key to maintaining a healthy cardiovascular system is to maintain hemostatic balance. Once pathogenic thromboembolism occurs, disruption of hemostatic balance can lead to major fatal diseases such as ischemic stroke, myocardial infarction, pulmonary embolism, peripheral arterial occlusion, deep vein thrombosis, and other diseases caused by thromboembolism. Pathological thrombi (blood clots) are dissolved into soluble components in the body by plasmin (Plm), a serine protease derived from plasminogen (Plg). Plg forms clots by binding to both fibrin and fibrinogen. Plg can be converted to Plm by both tissue-type Plm activator (tPA) and urokinase-type Plm activator (uPA), which are specific Plg activators in the body. Plg activators have been developed as thrombolytic drugs for the treatment of thromboembolic diseases. Currently, in the United States, the only proven drug for the treatment of acute ischemic stroke is tPA. However, it is well known that tPA is not an "ideal thrombolytic drug" for the following reasons: first, the efficacy of treating ischemic stroke within 3 hours is only 10%; second, the significant (2%) fatal bleeding side effect (intracranial hemorrhage) limits the need for treatment within 4.5 hours; third, the effectiveness of Plg activator drugs (PAs including tPA and uPA) depends on the presence of Plg in the clot. For certain clots during thrombolytic therapy with high-dose tPA or uPA, such as the stretching and contracting clots present in long-term thromboembolism (such as deep vein thrombosis), there is Plg depletion that may end the efficiency of the thrombolytic drug.

[0003] To address the “Plg depletion” problem, it has been suggested that direct thrombolysis based on Plm may have advantages, as Plm can directly dissolve pathogenic clots. However, Plm is immediately neutralized by α2-antithrombin (α2-AP) in the blood, and its half-life in vivo is only 0.2 seconds. In fact, recombinant μPlm (catalytic domain of Plm) produced by Pichia pastoris (Y-μPlm) has been approved by the US FDA in 2012 for the treatment of symptomatic vitreous macular adhesions, but encountered obstacles when trying to develop it into a thrombolytic drug for ischemic stroke and acute peripheral arterial occlusion (published in two clinical trials: NCT00123305 and NCT00123292). One possible reason is that when using recombinant μPlm as a direct thrombolytic agent, the drug needs to reach a sufficient concentration (a critical concentration for a single patient) to overcome α2-AP inhibition to effectively dissolve the clot. The normal blood concentration of α2-AP is about 1 μM, so thrombolytic therapy requires more than 1 μM of μPlm (critical concentration) to effectively neutralize α2-AP. As the concentration of μPlm increases overwhelmingly, the risk of fatal bleeding side effects also increases. In fact, this difficulty leads to the "Plm dilemma": at low doses (below the concentration that neutralizes α2-AP), the drug is ineffective; but in clinical applications, complete neutralization of α2-AP can cause fatal bleeding side effects. Even in the case of local catheter-directed delivery, the local concentration of Plm must reach >1 μM to achieve a therapeutic effect. On the other hand, "excessive" Plm may reach distal stops to protect blood vessels from bleeding and dissolve their thrombi, which can cause bleeding side effects.

[0004] μPlm is the catalytic domain of the natural enzyme Plm that dissolves blood clots. Recombinant μPlm extracted from a strain of Pichia pastoris is an approved drug for the treatment of an eye disease called vitreomacular adhesion, but faces obstacles in developing into a thrombolytic drug for more serious diseases such as acute ischemic stroke. The inventors of the present application found that recombinant μPlm (E-μPlm) produced by Escherichia coli (E. coli) has unexpected and significant differences compared to Y-μPlm, although their functional primary structures are exactly the same. First, E-μPlg, as the zymogen version of E-μPlm, is unstable and can be automatically activated, which is a feature not found in any other version of Plg, whether natural or recombinant. Second, the melting temperature of E-μPlg is significantly lower than that of Y-μPlg. Third, the in vivo half-life of E-μPlm is significantly shorter than that of Y-μPlm. Fourth, animal experiments have shown that E-μPlm is effective in treating thromboembolic diseases but has reduced bleeding side effects. Based on these results, the inventors of the present application have proposed a strategy to overcome the long-standing bleeding problem faced by thrombolytic therapy. This strategy is summarized as the "hit-to-death" theory, which describes an "ideal thrombolytic drug". This "ideal drug" can be delivered to the pathogenic thrombus to effectively dissolve the thrombus, but due to its short half-life in the body, it disappears immediately after the thrombus is dissolved. Therefore, the often fatal bleeding side effects caused by the persistent proteolytic activity of current thrombolytic drugs can be avoided. In this article, the inventors of the present application present evidence that E-μPlm developed by the inventors of the present application may be close to the "ideal thrombolytic drug".

[0005] To solve the "Plm dilemma" problem, the inventors of the present application described two different strategies in our previous publications. One is to overcome the inhibitory effect of α2-AP, and the other is to reduce or eliminate the bleeding side effect. For the first strategy, the inventors of the present application designed a method to screen and select α2-AP escape mutants. Towards this direction, the inventors of the present application used a structure-based protein engineering strategy to improve the catalytic activity of μPlm while resisting the inhibition of α2-AP. Some of the results have been published and further described in our review article. For the second strategy, the inventors of the present application proposed a "hit-and-die" approach. In contrast to the traditional approach of developing thrombolytic therapies that are more stable and have a longer half-life in vivo, the "hit-and-die" theory describes an "ideal thrombolytic drug" that can be delivered to the pathogenic thrombus, effectively dissolve it, but will soon die due to its short half-life in vivo. Therefore, the often fatal bleeding side effects caused by the persistent proteolytic activity of current thrombolytic drugs can be avoided. Unlike Y-μPlg expressed in yeast, μPlg produced by the E. coli expression system is an insoluble inclusion body and needs to be renatured in vitro to produce active proteins. There are significant differences between proteins renatured in vitro and naturally folded proteins. Generally speaking, sufficient proteins produced and renatured by E. coli are more unstable and have a shorter half-life in vivo than proteins produced by eukaryotic cells. Herein, the inventors of the present application provide evidence that E-μPlm developed by the inventors of the present application is significantly different from Y-μPlm and is closer to the "ideal thrombolytic drug". First, E-μPlg, as a zymogen version of E-μplm, is unstable and can be automatically activated, which is a feature that has never been found in other versions of Plg (including Y-μPlg). Secondly, the melting temperature of E-μPlg is significantly lower than that of Y-μPlg. The in vivo half-life of E-μPlm is significantly shorter than that of Y-μPlm. Fourth, animal experiments showed that E-μPlm was effective in treating thromboembolic diseases but had reduced bleeding side effects. This difference was surprising because E-μPlm and Y-μPlm have exactly the same primary structure, and in traditional concepts, the primary structure determines the secondary structure, which in turn determines the tertiary structure and the function of the protein. Summary of the invention

[0006] The present invention provides a recombinant human microplasmin expressed by Escherichia coli, wherein the surface residues of the catalytic domain in contact with α2-antiplasmin in the human microplasmin are individually changed by an alanine scanning mutagenesis method so that the recombinant human microplasmin expressed by Escherichia coli can dissolve disease-causing thrombi while avoiding the inhibition of α2-antiplasmin and the side effects of bleeding.

[0007] In some embodiments, the surface residues of the catalytic domain altered by alanine scanning mutagenesis in the recombinant human microplasmin expressed in E. coli are shown as loops 1-6, respectively, wherein

[0008] The nucleotide sequence of loop 1 is shown in SEQ ID NO:3, and the amino acid sequence of loop 1 is shown in SEQ ID NO:4;

[0009] The nucleotide sequence of loop 2 is shown in SEQ ID NO:5, and the amino acid sequence of loop 2 is shown in SEQ ID NO:6;

[0010] The nucleotide sequence of loop 3 is shown in SEQ ID NO:7, and the amino acid sequence of loop 3 is shown in SEQ ID NO:8;

[0011] The nucleotide sequence of loop 4 is shown as cagggtgac, and the amino acid sequence of loop 4 is shown as QGD;

[0012] The nucleotide sequence of loop 5 is shown as SEQ ID NO:9, and the amino acid sequence of loop 5 is shown as SEQ ID NO:10;

[0013] The nucleotide sequence of loop 6 is shown as SEQ ID NO:11, and the amino acid sequence of loop 6 is shown as SEQ ID NO:12.

[0014] In some embodiments, the recombinant human microplasmin expressed by the Escherichia coli is mutated and the surface residues of the catalytic domain are respectively marked as: Gly739Ala, Arg582Ala, Met585Ala, Lys607Ala, Phe587Ala, Ser608Ala, Arg610Ala, Glu641Ala, Pro642Ala.

[0015] In some embodiments, the microplasminogen of the recombinant human microplasmin expressed by E. coli is automatically activated at around pH 6.5.

[0016] In some embodiments, the in vivo half-life of the recombinant human microplasmin expressed by E. coli is about 14.3±1.6 minutes to about 28.5±1.1 minutes.

[0017] In some embodiments, the in vivo half-life of the recombinant human microplasmin expressed by E. coli and labeled with Phe587Ala is about 14.3±1.6 minutes.

[0018] In some embodiments, the recombinant human microplasmin is selected to be biologically active in cleaving and detoxifying pathogenic polypeptides or insoluble fibrin and to be resistant to inhibition by α2-antiplasmin.

[0019] The present invention also provides a method for producing the recombinant human microplasmin expressed by Escherichia coli, comprising the following steps: (1) performing alanine scanning mutagenesis on the surface residues of the catalytic domain of human microplasminogen to obtain the exogenous gene of the recombinant human microplasminogen expressed by the above-mentioned Escherichia coli; (2) inserting the exogenous gene into an E. coli expression system for expression, so as to obtain insoluble inclusion bodies of the recombinant human microplasminogen expressed by the E. coli; (3) renaturing and purifying the insoluble inclusion bodies in vitro to obtain the variant of the recombinant human microplasminogen expressed by the Escherichia coli; (4) activating the recombinant human microplasminogen expressed by the Escherichia coli into microplasmin using a plasminogen activator such as uPA; (5) Selecting mutants that have biological activity in cleaving and detoxifying pathogenic polypeptides or insoluble fibrin and are resistant to inhibition by α2-antiplasmin to obtain the recombinant human microplasmin expressed by E. coli as described above.

[0020] The present invention also provides a pharmaceutical composition, which comprises the recombinant human microplasmin expressed by Escherichia coli as a thrombolytic agent, or a pharmaceutically acceptable dosage form thereof, or a pharmaceutically acceptable solvate of the compound or dosage form, and includes a pharmaceutically acceptable excipient.

[0021] The present invention also provides a kit, which comprises the above-mentioned recombinant human microplasmin expressed by Escherichia coli as a thrombolytic agent, or a pharmaceutically acceptable dosage form thereof, or a pharmaceutically acceptable solvate of the compound or dosage form, and includes a pharmaceutically acceptable excipient.

[0022] The present invention also provides a use of the above-mentioned pharmaceutical composition for treating thromboembolism-related diseases.

[0023] The present invention also provides a use of the above kit for treating thromboembolism-related diseases.

[0024] The present invention also provides a method for treating thromboembolism-related diseases including ischemic stroke, myocardial infarction, deep vein thrombosis, peripheral arterial occlusion, pulmonary embolism and systemic blood coagulation caused by various disease conditions such as SARS-CoV2 infection and sepsis, wherein the method comprises administering a therapeutically effective amount of the above-mentioned pharmaceutical composition or a pharmaceutically acceptable dosage form thereof or a pharmaceutically acceptable solvate of the compound or dosage form to a subject suffering from the above-mentioned disease.

[0025] The present invention also provides a method for treating thromboembolism-related diseases including ischemic stroke, myocardial infarction, deep vein thrombosis, peripheral arterial occlusion, pulmonary embolism and systemic blood coagulation caused by various disease conditions such as SARS-CoV2 infection and sepsis, wherein the method comprises administering a therapeutically effective amount of the above-mentioned kit or a pharmaceutically acceptable dosage form thereof or a pharmaceutically acceptable solvate of the compound or dosage form to a subject suffering from the above-mentioned disease.

[0026] In some embodiments, in the above-mentioned method of treating thromboembolism-related diseases, the pharmaceutical composition is administered by intravenous, catheter-guided local administration, subcutaneous, submuscular and aerosol routes. definition

[0027] The term "in vivo half-life" as used herein refers to the time required for the concentration of a drug in the blood or the amount of the drug in the body to be reduced to half of its original concentration. 1 / 2 ) is calculated as: Where k is the elimination rate constant. As long as the K value of the drug is calculated, the half-life of the drug in vivo can be calculated according to the above formula. For example, if the blood concentration of a drug is 25% 2 hours after administration and 19% 5 hours after administration, then the elimination rate constant of the drug is The half-life of the drug Hour.

[0028] In the present disclosure, the "in vivo half-life" of plm-based therapies has two different definitions. The first definition is the in vivo enzyme activity half-life. Once Plm enters the blood at a low concentration (<1 μM, i.e., the serum concentration of α2-AP), it is immediately neutralized by its main inhibitor α2-AP, and its activity half-life is only 0.2 seconds, while the activity half-life of μPlm is relatively long, about 4 seconds. The second definition is the inherent structural stability of the protein itself in the blood. For example, recombinant μPlm renatured from Escherichia coli inclusion bodies is stable under laboratory conditions of controlled buffer and temperature, but once injected into the blood of surviving mice, the protein itself becomes unstable, with a structural half-life as short as 2.75 minutes; on the other hand, the in vivo structural half-life of natural Plg and Plm can be as long as 2-4 days. In the "hit and die" strategy, the inventors of the present disclosure used the second definition when describing in vivo stability and half-life. In the present invention, the "rapid death" of μPlm therapy does not come from the inhibition of protease inhibitors present in serum, but rather it is a situation where, at high concentrations (>1 μM), after neutralizing all inhibitor activity and dissolving targeted thrombi, the recombinant enzyme itself disintegrates, resulting in the loss of remaining enzyme activity.

[0029] The term "recombinant" used herein means that the recombinant vector is obtained by translating the designed gene into a protein fragment and by gene recombination technology.

[0030] The term "renaturation" as used herein refers to the process by which artificially denatured proteins acquire their functional structure and conformation. Through this physical process, proteins fold from random coils into specific functional three-dimensional structures. When translated from mRNA sequences into linear peptide chains, proteins initially exist in the form of unfolded polypeptides or random coils and renature to their native conformations by "natural" or "artificial" means.

[0031] The term "inclusion body" used herein refers to high-density (1.3 mg / ml) insoluble protein particles wrapped by the cell membrane formed when exogenous genes are expressed in prokaryotic cells, especially when overexpressed in Escherichia coli. When observed under a microscope, it appears as a high-refractive region and is significantly different from other components in the cytoplasm. Inclusion bodies generally contain more than 50% of recombinant proteins, and the rest are ribosomal components, RNA polymerase, endotoxin, outer membrane proteins, liposomes, lipopolysaccharides, etc., and are only soluble in denaturants such as high concentrations of urea, guanidine hydrochloride, etc. The size of the inclusion body is about 0.5 μm to 1 μm, and the diameter of the inclusion body in the cytoplasm of Escherichia coli is generally between 0.2 μm and 1.5 μm.

[0032] The term "mutant" as used herein refers to the introduction of a mutation in a single amino acid of a native protein or "wild-type (WT)" protein using genetic engineering methods such as PCR.

[0033] When used immediately before a numerical value, the term "about" refers to ±10% of the numerical value. For example, "about 40" refers to ±10% of 40 (i.e., from 36% to 44%), ± at most 10%, ± at most 9%, ± at most 8%, ± at most 7%, ± at most 6%, ± at most 5%, ± at most 4%, ± at most 3%, ± at most 2%, ± at most 1%, ± less than 1%, or any other value or value range therein.

[0034] The term "substantially" has its usual meaning as used in the art. For example, "substantially" may refer to "significantly", "quite substantially", "to a large extent", "mostly", or "essentially". In some embodiments, "substantially" may refer to at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0035] The term "binding domain" or "binding region" refers to a domain, region, portion or site of a binding domain derived from a protein, polypeptide, oligopeptide, peptide or antibody or an antibody that has specific recognition and binding to a target molecule (such as an antigen, ligand, receptor, substrate or inhibitor). Exemplary binding domains include single-chain antibody variable regions, receptor extracellular domains and ligands. In certain embodiments, the binding domain includes or consists of an antigen binding site (e.g., comprising a variable heavy chain sequence and a variable light chain sequence or three light chain complementary determining regions (CDRs) and three heavy chain CDRs from an antibody placed in an optional framework region (FR), examples of which are human framework regions FRs that optionally include one or more amino acid substitutions). A variety of assays are known for identifying binding domains of the present invention that can specifically bind to a particular target, including Western blotting, ELISA, phage display library screening and Interaction analysis.

[0036] If the binding domain or protein binds to the target with an affinity or Ka (i.e., the equilibrium binding constant of a specific binding interaction in units of 1 / M) equal to or greater than 105M1, without significantly binding to other components present in the test sample, the binding domain or protein "specifically binds" to the target. Binding domains can be divided into "high affinity" binding domains and "low affinity" binding domains. A "high affinity" binding domain refers to a binding domain with a Ka of at least 107M1, at least 108M1, at least 109M1, at least 1010M1, at least 1011M1, at least 1012M1, or at least 1013M1. A "low affinity" binding domain refers to a binding domain with a Ka value as high as 107M1, 106M1, 105M1. Alternatively, affinity can be defined as the equilibrium dissociation constant (Kd) of a specific binding interaction in units of M (e.g., 105M to 1013M). The affinity of binding domain polypeptides and single-chain polypeptides according to the present disclosure can be readily determined using conventional techniques.

[0037] The term "pharmaceutically acceptable" refers to molecular entities and compositions that generally do not produce allergic or other serious adverse reactions when administered using routes known in the art. Molecular entities and compositions approved by U.S. federal or state regulatory agencies or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeias for use in animals, particularly in humans, are considered "pharmaceutically acceptable."

[0038] The term "pharmaceutically acceptable excipient" refers to being pharmacologically and / or physiologically compatible with the well-known subject and active ingredient in the art (i.e., being able to cause the desired therapeutic effect without causing any adverse desired local or systemic effect). Pharmaceutically acceptable excipients include, but are not limited to, fillers, binders, disintegrants, coatings, adsorbents, anti-adhesives, lubricants, antioxidants, flavorings, coloring agents, sweeteners, solvents, cosolvents, buffers, chelating agents, surfactants, diluents, wetting agents, preservatives, emulsifiers, coatings, isotonic agents, absorption delaying agents, stabilizers, and tonic regulators. The selection of suitable excipients for preparing the desired pharmaceutical composition of the present invention is known to those skilled in the art. Exemplary excipients for the pharmaceutical composition of the present invention include saline, buffered saline, glucose, and water. In general, the selection of suitable excipients depends, among others, on the active agent used, the disease to be treated, and the desired dosage form of the pharmaceutical composition.

[0039] The term "nucleic acid", "nucleic acid molecule" or "polynucleotide" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. Unless otherwise specified, the term includes nucleic acids containing natural nucleotide analogs, which have similar binding properties to the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a specific nucleic acid sequence also implicitly includes conservatively modified variants and complementary sequences thereof as well as the sequence explicitly indicated.

[0040] The term "expression" refers to the biosynthesis of a product encoded by a nucleic acid. For example, in the case where a nucleic acid fragment encodes a target polypeptide, expression includes transcribing the nucleic acid fragment into mRNA and translating the mRNA into one or more polypeptides.

[0041] The term "Escherichia coli expression system" is an expression system that efficiently expresses genes through DNA recombination technology, and the genes encode protective antigens of pathogenic microorganisms in Escherichia coli. It is one of the most commonly used recombinant protein expression systems. The research on Escherichia coli expression system has advantages such as clear background, simple operation, and high expression level. Its expression level is significantly higher than that of mammalian expression systems, but there are also corresponding shortcomings, such as the inability of the Escherichia coli system to secrete the expressed protein into the extracellular space, the limited ability to form disulfide bonds, and the inability to achieve complex modifications of protein expression (such as glycosylation modification).

[0042] The terms "polypeptide", "protein", "peptide" or "encoded by a nucleic acid sequence" (i.e., encoded by a polynucleotide sequence, encoded by a nucleotide sequence) refer to the full-length native sequence of a naturally occurring protein, as well as functional subsequences, modified forms or sequence variants, as long as the subsequence, modified form or variant retains a certain degree of function of the natural full-length protein. In the methods and uses of the present invention, these polypeptides, proteins and peptides encoded by nucleic acid sequences may be defective, under-expressed or defective endogenous proteins in the subject receiving gene therapy, but are not required to be identical thereto.

[0043] The term "subject" refers to an organism, such as a mammal (e.g., a human, a non-human mammal, a non-human primate, a primate, a laboratory animal, a mouse, a rat, a hamster, a gerbil, a cat, a dog). In some embodiments, the subject is a mouse. In some embodiments, the human subject is an adult, a teenager, or a pediatric subject. In some embodiments, the subject is suffering from a disease, disorder, or condition, for example, a disease, disorder, or condition that can be treated in the manner provided herein. In some embodiments, the subject suffers from a disease, disorder, or condition associated with a thromboembolic-related disease. In some embodiments, the subject is susceptible to the effects of a disease, disorder, or condition. In some embodiments, susceptible subjects tend to and / or show an increased risk of developing a disease, disorder, or condition (compared to the average risk observed in a reference subject or population). In some embodiments, the subject shows one or more symptoms of a disease, disorder, or condition. In some embodiments, the subject does not show specific symptoms or features of a disease, disorder, or condition. In some embodiments, the subject does not show any symptoms or features of a disease, disorder, or condition. In some embodiments, the subject is a human patient. In some embodiments, the subject is an individual who is being and / or has been diagnosed and / or treated.

[0044] The term "substantially" refers to the quantitative condition of exhibiting the full or nearly full extent or degree of a target characteristic or property. One of ordinary skill in the art will appreciate that biological and chemical phenomena rarely, if ever, complete and / or progress to completion or achieve an absolute result. Thus, the term "substantially" is used herein to capture the inherent completeness in many biological and chemical phenomena that are potentially lacking.

[0045] As used herein, the terms "systemic administration," "systemically administering," "peripheral administration," and "peripherally administering" have their art-understood meanings and refer to administration of a compound or composition such that it enters the recipient's system.

[0046] The term "therapeutic agent" refers to any agent that has a therapeutic effect and / or causes a desired biological and / or pharmacological effect when administered to a subject. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, improve, alleviate, inhibit, prevent, delay the onset of, reduce the severity and / or reduce the incidence of one or more symptoms or characteristics of a disease, disorder and / or condition. The term "WT" has a meaning that can be understood in the technical field and refers to an entity with a natural structure and / or activity found in a "normal" (compared to a mutation, illness, pathology, etc.) state or context. It will be understood by those of ordinary skill in the art that wild-type genes and polypeptides typically exist in a variety of different forms.

[0047] The terms "treat," "treatment," or "treating" refer to any method for partially or completely alleviating, ameliorating, alleviating, inhibiting, preventing, delaying the onset of, reducing the severity of, and / or reducing the incidence of one or more symptoms or characteristics of a disease, disorder, and / or condition. Treatment may be administered to subjects who do not show signs of the disease, disorder, and / or condition. In some embodiments, treatment may be administered to subjects who only show early signs of the disease, disorder, and / or condition, e.g., to reduce the risk of developing pathology associated with the disease, disorder, and / or condition.

[0048] The term "therapeutically effective amount" refers to an amount that can produce the desired therapeutic effect of its administration. In some embodiments, the term refers to an amount that is sufficient to treat the disease, disorder or condition when administered to a population suffering from or susceptible to a disease, disorder or condition according to a therapeutic administration regimen. In some embodiments, a therapeutically effective amount is an amount that reduces the incidence and / or severity and / or delays the onset of one or more symptoms of the disease, disorder and / or condition. One of ordinary skill in the art will appreciate that the term "therapeutically effective amount" does not actually require successful treatment to be achieved in a particular individual. On the contrary, a therapeutically effective amount can be an amount that provides a specific desired pharmacological response in a large number of subjects when administered to a patient in need of such treatment. abbreviation

[0049] “AMI” stands for acute myocardial infarction; “AD” stands for Alzheimer’s disease; “α2-AP” stands for α2-antiplasmin; “AHA” stands for American Heart Association; “CDT” stands for catheter-directed thrombolysis; “μPlm” stands for microplasmin; “Plm” stands for plasmin; “Plg” stands for plasminogen; “tPA” stands for tissue-type plasminogen activator; “uPA” stands for urokinase-type plasminogen activator; “mPlg” stands for microplasminogen; “μPlg” stands for microplasminogen; “mPlm” stands for miniplasmin; “μPlm” stands for microplasmin; “PA” stands for plasminogen activator; “Kr” stands for RING domain; “CTT” stands for C-terminal tail; “PDB” stands for Protein Data Bank; “COVID-19” stands for coronavirus disease 2019 disease; “IB” stands for inclusion bodies; “M-WT” stands for mouse wild-type; “H-WT” stands for human wild-type; “ME-μPlm” stands for mouse microplasmin expressed in E. coli; “WT” stands for wild-type; “M-μPlg” stands for mouse microplasminogen; “HY-μPlg” stands for human microplasminogen expressed in yeast; “MY-μPlg” stands for mouse microplasminogen expressed in yeast; “H-μPlg” stands for human microplasminogen; “Y-μPlg” stands for microplasminogen expressed in yeast; “HE-μPlg” stands for human microplasminogen expressed in E. coli; “Y-μPlm” stands for microplasmin expressed in yeast; “E-μPlm” stands for microplasmin expressed in E. coli ; "E-μPlg" stands for microplasminogen expressed in E. coli; "IC50" stands for half of the maximal inhibitory concentration; "H-WT" stands for human wild type; "M-WT" stands for mouse wild type; "HE-WT" stands for E. coli expressing human wild type; "HE-μPlm" stands for human microplasmin expressed in E. coli; "Km" stands for Michaelis constant; "Kcat" stands for catalytic constant; "Kd" stands for dissociation constant; "Vmax" stands for maximum response velocity; "H-F587A" stands for human Phe587Ala; "F587A" stands for Phe587Ala; "R403" stands for Arg403; "M404" stands for Met404; "H603" "D646" represents Asp646; "S741" represents Ser741; "D735" represents Asp735; "S735" represents Ser735; "L763" represents Leu763; "G764" represents Gly764; "S736" represents Ser736; "P642A" represents Pro642Ala; "G739A" represents Gly739Ala; "K645A" represents Lys645Ala; "V720A" represents Val720Ala; "E724A" represents Glu724Ala; "F587R" represents Phe587Arg; "G739A" represents Gly739Ala;"R582A" represents Arg582Ala; "M585A" represents Met585Ala; "K607A" represents Lys607Ala; "S608A" represents Ser608Ala; "R610A" represents Arg610Ala; "E641A" represents Glu641Ala; "G739" represents Gly739; "F587" represents Phe587; "N717A" represents Asn717Ala; "G718A" represents Gly718Ala; "R719A" represents Arg719Ala; "V720A" represents Val720Ala; "Q721A" represents Gln721Ala; "S722A" represents S er722Ala; "T723A" represents Thr723Ala; "E724A" represents Glu724Ala; "L605A" represents Leu605Ala; "E606A" represents Glu606Ala; "P609A" represents Pro609Ala; "P611A" represents Pro611Ala; "S612A" represents Ser612Ala; "T581A" represents Thr581Ala; "F583A" represents Phe583Ala; "G584A" represents Gly584Ala; "H586A" represents His586Ala; "Q738A" represents Gln738Ala; "D740A" represents Asp7 40Ala; "S760A" represents Ser760Ala; "W761A" represents Trp761Ala; "G762A" represents Gly762Ala; "L763A" represents Leu763Ala; "G764A" represents Gly764Ala; "P642A" represents Pro642Ala; "T643A" represents Thr643Ala; "R644A" represents Arg644Ala; "H621A" represents His621Ala; "Q622A" represents Gln622Ala; "E623A" represents Glu623Ala; "V624A" represents Val624Ala; "N625A" represents Asn625A la; "L626A" represents Leu626Ala; "E627A" represents Glu627Ala; "P628A" represents Pro628Ala; "H629A" represents His629Ala; "T688A" represents Thr688Ala; "Q689A" represents Gln689Ala; "G690A" represents Gly690Ala; "T691A" represents Thr691Ala; "F692A" represents Phe692Ala; "G693A" represents Gly693Ala; "G695A" represents Gly695Ala; "L696A" represents Leu696Ala; "F785C" represents Phe587Cys;"F785D" represents Phe587Asp; "F785E" represents Phe587Glu; "F785G" represents Phe587Gly; "F785H" represents Phe587His; "F785I" represents Phe587Ile; "F785K" represents Phe587Lys; "F785L" represents Phe587Leu; "F785M" represents Phe587Met; "F785N" represents Phe587Asn; "F785P" represents Phe587Pro; "F785Q" represents Phe587Gln; "F785R" represents Phe587Arg; "F785S" represents Phe587Ser; "F785T" represents Phe587Thr; "F785V" represents Phe587Val; "F785W" represents Phe587Trp; "F785Y" represents Phe587Tyr. ; BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 The nucleotide sequence and amino acid sequence of the designed mutant human μPlg loop known in the art are shown, and each sequence can be described as:

[0051] The cDNA sequence of natural human μPlg can be found in SEQ ID NO: 1; the amino acid sequence of natural human μPlg can be found in SEQ ID NO: 2;

[0052] The cDNA sequence of loop 1 in mutant human μPlg can be found in SEQ ID NO:3, wherein the cDNA starts from g298 to a312; the amino acid sequence of loop 1 in mutant human μPlg can be found in SEQ ID NO:4, wherein the amino acids start from Glu1 to Lys5;

[0053] The cDNA sequence of loop 2 in natural human μPlg can be found in SEQ ID NO:5, wherein the cDNA starts from t190 to a213; the amino acid sequence of loop 2 in mutant human μPlg can be found in SEQ ID NO:6, wherein the amino acids start from Leu1 to Pro8;

[0054] The cDNA sequence of loop 3 in mutant human μPlg can be found in SEQ ID NO:7, wherein the cDNA starts from a118 to g132; the amino acid sequence of loop 3 in mutant human μPlg can be found in SEQ ID NO:8, wherein the amino acids start from Thr1 to Met5;

[0055] The cDNA sequence of mutant human μPlg loop 4 is cagggtgac; the amino acid sequence of mutant human μPlg loop 4 is QGD;

[0056] The cDNA sequence of loop 5 of mutant human μPlg can be found in SEQ ID NO:9, wherein the cDNA starts from t655 to t669; the amino acid sequence of loop 5 of mutant human μPlg can be found in SEQ ID NO:10, wherein the amino acid starts from Ser1 to Gly5;

[0057] The cDNA sequence of loop 6 in mutant human μPlg can be found in SEQ ID NO: 11, wherein the cDNA starts from a526 to a549; the amino acid sequence of loop 6 in mutant human μPlg can be found in SEQ ID NO: 12, wherein the amino acids start from Asn1 to Glu8.

[0058] Figure 2 A detailed view of the active site is shown, where residues S741, H603, and D646 form a catalytic triad to initiate a covalent reaction with the backbone amide between R403 and M404 of α2-AP.

[0059] Figure 3 The active site is shown to be stabilized by an extended hydrogen bond with the side chain of the key residue R403 of α2-AP.

[0060] Figure 4 An example of Michaelis-Menten kinetic measurement of wild-type (WT) μPlm is shown.

[0061] Figure 5 The comparison of the inhibitory effects of α2-AP on the wild type (WT) and F587A is shown, and it can be seen that the inhibitory effect of α2-AP on F587A is reduced.

[0062] Figure 6 The kinetic parameters of loop 1 and α2-AP inhibition are shown, as are their specific activities and fold increase in IC50 against α2-AP, where 1 represents the fold of catalytic efficiency and 2 represents the fold of IC50 relative to wild type (WT).

[0063] Figure 7 The kinetic parameters of loop 2 and α2-AP inhibition are shown, as are their specific activities and fold increase in IC50 against α2-AP, where 1 represents the fold of catalytic efficiency and 2 represents the fold of IC50 relative to wild type (WT).

[0064] Figure 8 The kinetic parameters of loop 3 and α2-AP inhibition are shown, as are their specific activities and fold increase in IC50 against α2-AP, where 1 represents the fold of catalytic efficiency and 2 represents the fold of IC50 relative to wild type (WT).

[0065] Fig. 9The kinetic parameters and α2-AP inhibition of loop 4 and loop 5 are shown, as are their specific activities and fold increase in IC50 against α2-AP, where 1 represents the fold of catalytic efficiency and 2 represents the fold of IC50 relative to wild type (WT).

[0066] Fig.10 The kinetic parameters and α2-AP inhibition of loop 6 are shown, as are their specific activities and fold increases in IC50 against α2-AP, where 1 represents the fold of catalytic efficiency and 2 represents the fold of IC50 relative to wild type (WT).

[0067] Fig.11 The kinetic parameters of loop 7 and α2-AP inhibition are shown, as are their specific activities and fold increase in IC50 against α2-AP, where 1 represents the fold of catalytic efficiency and 2 represents the fold of IC50 relative to wild type (WT).

[0068] Fig.12 The kinetic parameters of loop 8 and α2-AP inhibition are shown, as are their specific activities and fold increases in IC50 against α2-AP, where 1 represents the fold of catalytic efficiency and 2 represents the fold of IC50 relative to wild type (WT).

[0069] Fig.13 The kinetic parameters and α2-AP inhibition of the F587 mutant are shown. Their specific activities and IC50s for α2-AP are increased exponentially, and the results of saturation mutations at position 587 are presented here, where 1 represents the multiple of catalytic efficiency and 2 represents the multiple of IC50 relative to wild type (WT).

[0070] Fig.14 Shown is a summary of the calculation results of the in vivo half-life of E-μPlm / Y-μPlm.

[0071] Fig.15 The results of the in vivo half-life calculation of H-F587AμPlm expressed in E. coli are shown.

[0072] Fig.16 The in vivo half-life calculation results of human wild-type μPlm expressed in E. coli are shown.

[0073] Fig.17 The mutation map on the interface between α2-AP and the surface residues of the catalytic domain is shown, where the interaction positions of the nine mutants on μPlm with α2-AP are shown in Figure 2. Fig.17 As shown in A, the sites and escape indices of the nine mutants are marked on Fig.17 In B.

[0074] Fig.18SDS-PAGE of purified μPlg and μPlm variants is shown, wherein (A) represents E-μPlg purification by superdex 200, 1: marker, 2: M-WT unreduced; 3: M-WT reduced; 4: H-WT unreduced; 5: H-WT reduced; 6: H-F587A unreduced; 7: H-F587A reduced; (B) represents E-μPlg purified by SPXL, wherein 1: marker, 2: M-WT unreduced; 3: M-WT reduced; 4: H-WT unreduced; 5: H-WT reduced; 6: H-F587A unreduced; 7: H-F587A reduced; (C) represents E-μPlm purified by SPXL, wherein 1: F587A marker, 2 : M-WT unreduced; 3: M-WT reduced; 4H-WT unreduced; 5: H-WT reduced; 6: H-F587A unreduced; 7: H-F587A reduced; (D) represents the expression and purification of mouse Y-μplm (MY-μplm) by affinity column gel-(1) on the left and SP cation exchange column gel-(2) on the right; (E) represents SDS-PAGE, which is a direct comparison of sp column purified MY-μPlm (gel 1, left) and HY-μPlm (gel 2, right). The arrow in the figure indicates that after activation, μPlm is cut into two molecules, but connected by a disulfide bond. The results show that the unreduced lane still shows a complete molecule, while the reduced lane shows two smaller molecules.

[0075] Fig.19 μPlg and μPlm purified by Superdex 200SEC and SP XL cation exchange column chromatography. (a) H-WTμPlg purified by Superdex 200; (b) M-WTμPlg purified by Superdex 200; (c) H-F587AμPlg purified by Superdex 200; (d) H-WTμPlg purified by SP XL; (e) M-WTμPlg purified by SPXL; (f) H-F587AμPlg purified by SPXL; (g) H-WTμPlm purified by SP XL; (h) M-WTμPlm purified by SP XL; (i) H-F587AμPlm purified by SP XL, H-WT refers to human wild type; M-WT refers to mouse wild type; F587A human refers to F587A mutant.

[0076] Fig. 20Typical animal experiments and results are shown, where in the tissue sections, the top panel (I) is a lung section: left, thrombin causes thrombosis; middle, control group, no thrombin, no thrombus; right, thrombin plus ME-μPlm, no thrombus. The lower panel (II) is a heart section: left, thrombin coagulation causes coagulation death of mice, and the heart is bloodless; middle, control group, no thrombin, normal heart; right, thrombin plus ME-μPlm, normal heart. Specific embodiments

[0077] The above written description is considered sufficient to enable one skilled in the art to practice the present disclosure.The above description and examples detail certain exemplary embodiments of the present disclosure. However, it should be understood that no matter how detailed the foregoing appears in text, the disclosure can be implemented in many ways and the disclosure should be construed in accordance with the appended claims and any equivalents thereof.

[0078] All references cited herein, including patents, patent applications, articles, textbooks, etc. and references cited therein, are hereby incorporated by reference in their entirety, if not already cited.

[0079] The present invention is further described in detail with reference to the following experimental examples. These examples are provided for illustrative purposes only and are not intended to be limiting unless otherwise stated. Therefore, the present invention should not be interpreted in any way as being limited to the following examples, but should be interpreted as covering any and all variations that become apparent due to the teachings provided herein. Expression of recombinant H-μPlm in E. coli

[0080] As described above, the present invention describes a concept and product that, in developing PLM-based therapeutics, such as μPLM-based thrombolytic therapy, one would like to design a therapeutic approach that can effectively dissolve pathogenic thrombi while escaping or overcoming the inhibitory effects of α2-AP, but also loses activity after the therapeutic action due to instability in vivo and short in vivo half-life, thereby avoiding bleeding side effects. This concept and product is "novel" because the conventional wisdom is that when developing protein therapeutics, including thrombolytic agents, one always wants to obtain greater in vivo stability and longer in vivo half-life.

[0081] Therefore, the first aspect of the present invention provides a recombinant human μPlm expressed by E. coli, which μPlm can be just unstable in vivo at an appropriate activity level, which is long enough to dissolve disease-causing blood clots but not long enough to dissolve protective hemostatic plugs, wherein the present disclosure also discloses that some mutants can be characterized as better or almost the same as the wild type. In view of this, the in vivo half-life of the recombinant μPlm of the present disclosure is designed and selected to be in the range of about 14.3±1.6 minutes to about 22.3±1.1 minutes, which is long enough to dissolve disease-causing blood clots, but short enough to lose activity after the therapeutic effect, thereby avoiding bleeding side effects.

[0082] The nucleotide and amino acid sequences of natural human μPlm are as follows Figure 1 As shown, its nucleotide sequence and amino acid sequence are shown in SEQ ID NO: 1-2, wherein the surface residues of the catalytic domain contacting α2-AP in human μPlm are subjected to alanine scanning mutagenesis, so that the recombinant human μPlm expressed by E. coli can both dissolve the thrombus that causes the disease and avoid the bleeding side effect. Figure 1 As shown, in the recombinant human Plm expressed in E. coli, the surface residues of the catalytic domain mutated by alanine scanning mutagenesis are shown as loops 1-6, and their nucleotide and amino acid sequences are shown as SEQ ID NOs: 3-12.

[0083] The inventors of this application superimposed the crystal structures of individual proteins onto trypsin: The antitrypsin crystal structure (PDB ID: 1OPH) was used as a template. Figure 2 and Figure 3 The interface interactions between α2-AP and μPlg are shown in the loop of α2-AP that docks with the μPlm active site. Figure 2 The main chain amide between R403 and M404 of α2-AP is shown as the reaction site, which interacts with the catalytic triad of μPlm, H603, D646, and S741. adjacent, the distance between S741 and the main chain amide is approximately Indicates that it is in a pre-attack stance. Figure 3 The active site is shown to be maintained by an extensive hydrogen bonding grid including the side chains of R403, D735 and S735 and the backbone carbonyls of L763, G764 and S736. Cloning, expression, inclusion body renaturation and purification of recombinant human μPlm expressed in Escherichia coli

[0084] The optimized synthetic genes of WT and mutant human μPlm for E. coli expression are the same as those of US17 / 709403. The procedures for E. coli expression, inclusion body purification, renaturation and purification are also the same as those of the prior art. The sequence-verified mutant plasmids were transformed into E. coli strain BL21 (DE3) for expression, renaturation and purification, and the steps were the same as those of the prior art. Briefly, E. coli containing the expression plasmids were expressed in a high-density shake flask automatic induction system. The liquid culture medium was then rotated at a reduced speed, the particles were continuously washed, and freeze-thaw cycles were performed with lysozyme to purify IB. The purified inclusion bodies were dissolved in 8M urea buffer (8M urea, 0.1M triisopropyl ethanesulfonyl (Tris), 1mM glycine, 1mM EDTA, 10mM mercaptoethanol, 10mM dithiothreitol (DTT), 1mM reduced glutathione (GSH), 0.1mM oxidized glutathione (GSSG), pH 10.5, and a final concentration of 2mg / ml). The solution was rapidly diluted to 20 volumes of 20 mM triisopropyl ethanesulfonyl (Tris), 0.2 M L-arginine, pH 10.5. The pH of the solution was slowly adjusted to pH 8 with 6 M hydrochloric acid. The folded protein was then concentrated by ultrafiltration and then purified by various column chromatography. For the initial screening, the inventors of the present application provided 200 ml of culture medium for WT μPlg and each mutant, and each construct produced approximately 200 mg of high purity IB.

[0085] Human α2-AP (HAP) and mouse α2-AP (MAP) were folded in a buffer containing 20 mM triisopropyl ethanesulfonyl (Tris), 0.1 mM glutathione (GSH), 0.01 mM oxidized glutathione (GSSG), pH 9.0, and the purification results were basically the same as μPlg. The expression and purification of streptokinase and staphylokinase were basically the same as those published (Cloning, expression, purification and activity study of high-yield recombinant staphylokinase in bacterial expression system). Enzymatic Assay and Kinetic Measurement of Recombinant Human μPlm Expressed in Escherichia coli

[0086] The inventors of the present application first performed standard Michaelis-Menten kinetic measurements on WT and all purified mutants, where WT and F587A mutants are exemplified as follows: Figure 4 and Figure 5 The inventors of the present application then performed α2-AP inhibition studies using the WT enzyme as a reference for each set of experiments. Figure 4 An example of a Michealis-Menten kinetic measurement of WT μPlm is shown. Figure 5Shown in the figure are examples of inhibition curves of WT and F587A, one by one. It can be clearly seen that at high concentrations of α2-AP, WTμPlm loses almost all of its activity, while the F587A mutant is still active, retaining nearly half of its activity at the highest concentration of the inhibitor.

[0087] The complete set of measurement results is shown in the form of a bar graph. Figure 6-13 Shown: Error bars not illustrated for clarity. Table 1 shows the kinetic parameters for loop 2 and loop 3 alanine mutants, demonstrating improved catalytic efficiency (Kcat / Km) for F587A, exemplifying the measured parameters with standard errors. Table 1

[0088] The chromogenic substrate pGlu-Phe-Lys-pNA (S-2403) was used for general μPlm enzyme assays and kinetic studies. For μPlm enzyme assays in mouse plasma samples for in vivo half-life studies, a more sensitive fluorescent assay kit was used using Abcam (Plm Activity Assay Kit (Fluorometric Assay) (ab204728) according to the manufacturer's instructions. The assay mixture contained 2μl plasma, 2μl fluorescent substrate (Suc-Ala-Phe-Lys-AMC) and 96μl assay buffer provided by the manufacturer.

[0089] The results of kinetic measurements are essentially the same as those of US17 / 709403. The proteolytic activity was monitored using the chromogenic substrate pGlu-Phe-Lys-pNA (S-2403), and the μPlm active site was titrated using 4-nitrophenyl-4-guanidinebenzoic acid hydrochloride (pNPGB). Briefly, recombinant μPlg proenzyme (35.5 μM) was activated for 10 minutes at 37°C using a Plg activator such as urokinase (20:1) in a reaction mixture containing 25 mM Tris-HCl, pH 7.4, 50 mM NaCl. The active site of μPlm was titrated using pNPGB as described. The activated proenzyme is diluted to 5.5 μ M, then 10 μ l proenzyme and 100 μ l of 0.0625mM, 0.125mM, 0.25mM, 0.5mM, 0.75mM, 1.0mM, 1.5mM, 2.0mM substrate S-2403 are mixed in assay buffer (25mM Tris-HCl, 50mM NaCl, pH 7.4). Use the microplate reader from Sai Mo Fei Shi Er (ThermoFisher), at 37 ℃, continue the generation (at 405nm) of monitoring starch enzymolysis activity with 10 seconds interval for 20 minutes. Use GraFit version 7 (Erithacus Software) that data are plotted as the relation of speed and substrate, and determine the Vmax and Km of WT and each mutant μ P1m. Calculate catalytic efficiency (Kcat / Km) according to the concentration of activated enzyme.

[0090] The chromogenic substrate pGlu-Phe-Lys-pNA (S-2403) was from Chromogenix (Sweden). 4-Nitrophenyl-4-guanidinobenzoate hydrochloride (pNPGB) was from Aldrich. NUPAGE 4-12% BTGEL was from Invitrogen. Other chemicals and protein reagents were from SIGMA / Aldrich. The kinetic measurement method was performed similarly to the description. Briefly, 35.5 μM of the folded and purified μPlg proenzyme was activated at 37°C for 4 minutes using a Plg activator such as urokinase (20:1) in a reaction mixture containing 25 mM Tris-HCl, pH 7.4, 50 mM NaCl. As described, pNPGB was used to titrate the active site of the activated μPlm. The activated proenzyme is diluted to 5.5 μ M, then the proenzyme of 10 μ l is mixed with 0.0625mM, 0.125mM, 0.25mM, 0.5mM, 0.75mM, 1.0mM, 1.5mM, 2.0mM substrate S-2403 of 100 μ l in experimental buffer (25mM Tris-HCl, 50mM NaCl, pH7.4).Use SpectraMax 250 type microplate reader (Molecular Devices), at 37 ℃, continue to monitor the generation (at 405nm) of enzymolysis activity in 20 minutes with 10 seconds interval.Use GraFit version 7 (Erithacus Software) that data are plotted as the relation of speed and substrate, and determine the Vmax and Km of WT and each mutant μ P1m.Calculate catalytic efficiency (Kcat / Km) according to the concentration of active enzyme. Starting from the crystal structures of μPlm (PDB code: 1BML) and α2-AP (PDB code: 2R9Y), the μPlm:α2-AP complex was constructed by homology modeling. These two structures were superimposed on the crystal structure of the trypsin:antitrypsin complex (PDB ID: 1OPH) to form the complex. The crystal structure of 2R9Y lacks the C-terminal residues, so the inventors of the present application used the I-TASSER server to construct the missing residues 465-491. The protein complex was then dissolved in a rhombic dodecahedane solvent box of water molecules represented by the TIP3P56 model, and the size of the simulation unit cell was determined to be at least 1 / 400 μm away from any atom of the protein. Adding counter ions (K + and Cl - ) to ensure electrostatic neutrality corresponding to an ion concentration of approximately 150 mM. All protein covalent hydrogen bonds were constrained using the LINCS algorithm, and long-range electrostatic interactions were treated using the particle mesh Ewald method with a real-space cutoff of Parallel simulations were performed using GROMACS4.6 in the CHARMM36a1 force field. The system was minimized using the most aggressive algorithm to remove bad contacts and then gradually heated to 300 K at a constant volume over 1 ns, using force constants of 20 for the heavy atoms of proteins and nucleotides. These constraints are gradually relaxed in subsequent 5 ns constant-pressure (1 atm) and constant-temperature (300 K) simulations. The system is reequilibrated for another 10 ns without position restraints. The pressure is kept constant using a Parrinello-Rahman barostat and the temperature is kept constant using a V-rescale thermostat with a time step of 2 fs. The system is simulated for 100 ns and snapshots are recorded every 20 ps.

[0091] Figure 6 The inhibition kinetics of loop 1 are shown, corresponding to a portion of the "94-pentose phosphate cycle" loop in μPlm that is connected to the active site D646. The relative catalytic efficiency (kcat / Km, a multiple increase of WT) of P642A was significantly reduced, but the IC50 value was improved by 2 orders of magnitude. The low activity of P642A is due to the large increase in Km. Although the relative catalytic efficiency of the K645A mutation increased by two times, the IC50 remained unchanged.

[0092] Figure 7 The inhibition kinetics of loop 2 are shown, corresponding to a portion of the "60-loop" of μPlm, extending from the active site H603. The figure shows that the P610A mutation leads to higher catalytic activity and a concomitant increase in IC50.

[0093] Figure 8 The inhibitory kinetics of loop 3 are shown, corresponding to the "37-loop" of μPlm. The four alanine mutants in loop 3 have higher catalytic activity than the WT enzyme. The main goal of this study was to find mutations with enhanced catalytic activity while resisting or being able to "escape" the inhibitory effects of α2-AP. Among all the alanine mutants scanned by the inventors of the present application, the F587A mutant was the best candidate. Therefore, the inventors of the present application selected the F587 position for saturation mutagenesis.

[0094] Fig. 9 The inhibition kinetics of mutations in loops 4-5 are shown, which are the "oxyanion stabilizing loop" of μPlm and the loop containing the "S1 entry box", respectively. Clearly, mutations in both loops 4 and 5 result in a significant loss of catalytic activity. G739A shows lower catalytic efficiency (0.6 times Kcat and 4.9 times Km), but α2-AP has no inhibitory effect on G739A in the range of up to 400 nM. This finding suggests that more research can be directed to this position. The loss of catalytic efficiency of G739A is mainly caused by an increase in Km.

[0095] Fig.10 The kinetics of inhibition by amino acid changes in loop 6 (referred to as the "methionine loop" in μPlm) are described. The inventors of the present application found that mutations in loop 6 also resulted in a dramatic loss of catalytic activity, which could be attributed to an increase in Km, particularly V720A (Kcat factor of 0.1, Km factor of 3.3) and E724A (Kcat factor of 0.1, Km factor of 5.2).

[0096] Fig.11 Loop 7 (also called "Ca 2+ As a result of mutations in the "binding" loop), loop 7 is the 70-80 loop of the μPlm structure. Although loop 7 is far from the active site, a loss of catalytic activity was observed upon alanine mutation of this loop.

[0097] Fig.12 Shown is the activity profile of loop 8, the "autolysis loop" of μPlm, which is inactive to amino acid mutations and is therefore not susceptible to inhibition by α2-AP.

[0098] Finally, the inventors of this application show that Fig.13 The kinetics of saturation mutations of Phe587 are shown, with five mutants gaining catalytic activity and showing greater resistance to α2-AP inhibition compared to wild-type. Of these mutants, F587A and F587R are identical and have desirable properties. Thermal stability of recombinant human μPlm expressed in Escherichia coli

[0099] Thermal stability was determined using a fluorescence-based thermal denaturation assay (differential scanning fluorescence, DSF). Measurements were performed using PCR tubes of the Bio-Rad CFX96 Real-Time PCR System (USA). A typical 40 μl reaction mixture contained SYPRO Orange 5X dye (purchased from Thermo Fisher Scientific), 2.5 μM, 5 μM and 10 μM μPlg in 20 mM HEPES buffer, pH 7.5. The reaction plate was incubated at 25°C for 30 minutes and then heated to 100°C at intervals of 0.5°C with a sedimentation time of 30 seconds. The "scan mode" was set to "FRET" and the fluorescence counts were plotted versus temperature. Fluorescence was measured with excitation at 470 nm and emission at 570 nm. In vivo expression of recombinant human μPlm expressed in Escherichia coli half life

[0100] In order to determine the half-life in vivo, the present invention injected 100 μL of μPlm sample diluted with PBS into the tail vein of the test mouse. Eye blood was collected at the specified time, and the sample was collected in a 1 ml anticoagulant centrifuge tube. The μPlm enzyme activity was directly measured with the obtained plasma, and the mouse blood sample was used as a control. The summary of the 6 independent measurement results showed that ME-μPlm had the shortest half-life, as shown in Figure 2. Fig.14 The in vivo half-life is summarized in Table 2. Table 2 μPlm YM-WT EM-WT EH-F587A EH-WT EM-WT EH-F587A Injection volume (mg) 0.4(9μM) 0.8(18μM) 0.8(18μM) 0.8(18μM) 0.8(18μM) 0.8(18μM) <![CDATA[t 1 / 2 (minutes)]]> 53.02±14.59 3.01±0.47 14.3±1.61 22.29±1.12 2.75±0.09 28.52±1.05

[0101] The inventors of this application specifically measured 0.8 mg Fig.15 The in vivo half-life of H-F587A μPlm expressed in E. coli is shown in Fig.16 HE-WT μPlm control is shown, while F587A-t 1 / 2 : 14.3±1.61 min, HE-μPlm-t 1 / 2 : 22.29±1.12 minutes, which means that E-μPlm F587A may develop into an “ideal thrombolytic drug”. Expression, purification and kinetics of recombinant human μPlm expressed in Escherichia coli

[0102] The inventors of the present application describe the screening and characterization of a total of 71 μPlm mutant clones, with the aim of selecting μPlm variants that can escape the inhibitory effect of α2-AP and also have good catalytic activity. On the basis of the above results, the inventors of the present application focused on the E. coli expression, inclusion body renaturation and purification of three recombinant μplgs, including WT H-μPlg, WT M-μPlg and the selected α2-AP escape mutants of H-μPlg, F587A (H-F587A). In addition, in order to compare the biochemical and kinetic properties of μPlg and μPlm expressed in E. coli and yeast, the inventors of the present application cloned both WTH-μPlg and M-μPlg into yeast expression vectors, expressed and purified the yeast-expressed recombinant proteins HY-μPlg and MY-μPlg.

[0103] Insoluble recombinant μPlm expressed in E. coli was renatured and purified to an active form for thrombolysis.

[0104] In order to experimentally determine the contribution of individual residues to complex formation, the inventors of the present application converted each amino acid residue in the μPlm loop to alanine (by means of alanine scanning mutagenesis) and mutated the alanine, wherein the alanine mutations were expressed as inclusion bodies in E. coli, renatured and purified. Based on the kinetic data of the mutant protein, the inventors of the present disclosure determined that F587A was the most ideal mutant and performed saturation mutagenesis on the F587 position. Interestingly, the F587A mutant resistant to α2-AP is consistent with published results, indicating that the mutant is resistant to certain active site small molecule inhibitors. The inventors of the present invention made a total of 73 mutant clones, 71 of which could be expressed and purified. Table 3 lists the kinetic parameters of the 9 most promising mutants selected from the mutagenesis results. The table summarizes the best mutants obtained from the alanine scanning mutagenesis data of reference. The kinetic values ​​of all mutants are expressed relative to the μPlm WT enzyme (WT, set to 1), where Kcat=442 (min -1 ), and Km = 204 μM. Kcat / Km is the catalytic efficiency, and IC50 is the inhibition of μPlm by α2-AP to half of the maximal activity. In the last column, Kcat / Km×IC50 represents an artificial value to define the "escape efficiency index". ∞ means no inhibition. Table 3 Summary of key required mutants

[0105] The table lists a column called Kcat / Km×IC50, which the inventors of the present disclosure define as the mutant "escape efficiency index" - the higher the index, the better the mutant. The index of F587A is 11.3, which is higher than the other mutants, but the index of G739A is off scale and needs more detailed study. Each mutant residue in Fig.17 The structures of the mutants are marked, with three mutants shown to be in contact with the model CTT structure (R582A, M585A, K607A) and five mutants in contact with the reactive central ring structure of α2-AP (K607A, S608A, R610A, E641A, P642A). F587A is the most promising escape mutant screened, with better catalytic activity and efficiency than WT, but with strong resistance to the inhibition of α2-AP. G739 is located very close to the active site S741, and G739A has low catalytic efficiency for synthetic substrates, but kinetic data show that this mutant completely avoids the inhibition caused by α2-AP. These results have found new directions for further research on the therapeutic development of plm-based drugs. The ultimate goal is to find gene-edited μPlm therapeutics through structure-based "directed engineering" of the enzyme, which will specifically degrade the target pathogenic peptide substrate, but have no activity or much lower activity against other non-target substrates. Preparation method of recombinant human μPlm expressed by Escherichia coli

[0106] The present application also provides a method for producing recombinant human μPlm expressed by E. coli. The method comprises the following steps:

[0107] (1) Alanine scanning mutagenesis is performed on the surface residues of the catalytic domain of human μPlg to obtain the exogenous gene of recombinant human μPlg expressed by Escherichia coli. Alanine is the chiral amino acid with the shortest side chain among amino acids. By mutating the amino acid residues to alanine, it is possible to study whether the function of the mutant protein is lost or changed due to the mutation, thereby locating the amino acid residues that have a key impact on the function of the protein. For example, one method to study the phosphorylation function of serine / threonine is to mutate T / S to A, making the site unable to be phosphorylated. Glycine has no side chain, and the introduction of glycine is relatively easy to change the structure of the protein, so glycine is generally not used. (2) The exogenous gene is inserted into the Escherichia coli expression system for expression to obtain insoluble inclusion bodies of recombinant human μPlm expressed by Escherichia coli. This step includes the following sub-steps:

[0108] (11) E. coli cell and gene verification: whether E. coli is infected with Chlamydia, its growth status, its transfection detection and foreign gene sequence verification;

[0109] (12) Design, preparation, screening of sgRNA and positive pool detection: design 4-6 sgRNAs, transfect sgRNAs and donors in different ways, screen the positive pool (resistance, fluorescence, drug or other pressure), and test the insertion efficiency of the positive pool in Escherichia coli cells;

[0110] (13) Screening culture medium for E. coli cells with inserted foreign genes: amplifying E. coli cell monoclones, verifying the inserted genes by PCR, and confirming the genotype of the E. coli cell monoclonal clones by functional verification such as Sanger sequencing;

[0111] (14) Quality testing and delivery of exogenous gene-transfected E. coli cells: Chlamydia detection and E. coli cell genotype verification, amplification and freezing.

[0112] (2) Inserting the foreign gene into the E. coli expression system for expression to obtain insoluble inclusion bodies of recombinant human microplasminogen expressed by E. coli.

[0113] (3) The insoluble inclusion bodies were renatured and purified in vitro to obtain mutants of recombinant human μPlg expressed by Escherichia coli. Fig.18 Shown is SDS-PAGE of column chromatography purified samples. Fig.18A shows the purity of μPlg purified by Superdex 200 column. The samples in lanes 2, 4, 6 were not reduced, and the samples in lanes 3, 5, 7 were reduced. The unreduced SDS-PAGE shows a lower molecular weight because the disulfide bonds in the protein molecule are intact and the "tethered" molecule is smaller in shape than the extended, reduced conformation. The most interesting results are as follows Fig.18 Shown in a is lane 3. This lane is M-μPlg run under simplified conditions, which shows that M-μPlg is partially auto-activated (arrows indicate two fragments after activation), while human μPlg (H-μPlg and H-F589A) is not activated (lanes 5, 7). The results clearly show that M-μPlg is not as stable as H-μPlg. Fig.18 B shows the SP XL column purity of the purified μPlg. In this case, lanes 2, 3, 5, and 7 show smaller molecular weights, indicating that μPlg is activated under this condition (pH 6.5). SDS-PAGE clearly shows that all versions of E. coli refolded μPlg are automatically activated to μPlm during the SP XL cation exchange column chromatography purification at pH 6.5. Fig.18 C shows the purity of μPlm purified by SPXL column under reducing (lanes 2, 4, and 5) and non-reducing (lanes 3, 5, and 7) conditions, and Fig.18 B similar pattern, which again shows that Fig.18 The μPlg in B are all activated. Fig.18 D shows the purification results of MY-μPlm expressed in the Pichia pastoris expression system. Gel experiments showed that yeast-expressed MY-μPlm was stable at pH 6.5 in both affinity purification gel-(1) and SPXL cation exchange column chromatography, as shown in gel-(2). In both cases, no auto-activation was observed using the same purification procedure as ME-μPlm. A direct comparison of E-μPlm and Y-μPlm purified by SP column is shown in Fig.18 As shown in E, it is clear that E-μPlm is automatically activated, while Y-μPlm is stable. Fig.18 E, firstly by affinity chromatography (Ni + - affinity column) to purify Y-μPlg expressed in Pichia pastoris, using a His-tag installed at the N-terminus of the recombinant protein, and then further purifying the affinity-purified protein using an SPXL column. This application provides several lines of evidence to demonstrate that E-μPlm is significantly different from Y-μPlm and may be developed into an "ideal thrombolytic drug." Fig.18 It was shown that both mouse and human E-μPlg can be autoactivated at pH 6.5, while Y-μPlg is stable and cannot be autoactivated under the same conditions. Fig.18A also shows that ME-μPlg can be activated automatically at pH 8, while HE-μPlg cannot be activated automatically under the same conditions. Fig.19 The purification profiles of recombinant μPlg by Superdex200SEC column chromatography and SP-Sepharose cation exchange chromatography are shown. As described above, the inclusion bodies expressed in E. coli were purified and renatured, and the renatured protein was first purified using a Superdex 200 column ( Fig.18 A, 18B, 18C), the second peak (renaturation peak, arrow) was further purified using an SPXL column ( Fig.19 D, 19E, 19F). Then, the purified μPlg was activated with streptokinase, and the activated μPlm was also purified using an SP XL column ( Fig.19 G, 19G, 19I).

[0114] (4) Activating the recombinant human microplasminogen expressed by the above-mentioned E. coli into microplasmin by a plasminogen activator. The recombinant human microplasminogen expressed by the above-mentioned E. coli is an inactive precursor of plasma plasmin and can be activated by various enzymes such as tissue activator t-PA and urokinase, or at the coagulation contact stage. In addition, exogenous activators such as streptokinase can also play a positive role. Plasmin degrades fibrin and fibrinogen and maintains the patency of blood vessels and glandular ducts.

[0115] (5) Select mutants that have biological activity in cleavage and detoxification of pathogenic polypeptides or insoluble fibrin and are resistant to the inhibitory effects of α2-antiplasmin to obtain recombinant human μPlm expressed in Escherichia coli. Once the desired residue is determined from alanine scanning mutagenesis, mutations will be made at the selected position to change all other 18 amino acid residues (except wild type and alanine), and further selection will be performed to determine the best mutation at the selected position. A second round of saturation mutagenesis was performed at the F587 site. In order to verify the alanine scanning mutagenesis strategy, 54 mutant μPlg expression vectors have been constructed. As an example, the test results of expression, renaturation and purification of 10 mutants are given, as well as the WT (wild type) μPlg enzyme. The expressed mutants belong to loop 2 (K607A, S608A, P609A, P611A), loop 3 (T581A, R582A, G584A, M585A, F587A) and loop 70-80 (Q622A). As shown in the figure, WT and mutant μPlm can be purified with one-step SEC after renaturation. This simplified purification procedure allows high-throughput screening of μPlm mutants. At equimolar or higher concentrations, α2-AP completely inhibits the activity of WT μPlm with a typical "biphasic" kinetic process. However, the inhibitory kinetics of mutant F587A are not "typical". Even at a 2-fold concentration of α2-AP and long-term incubation, mutant F587A still retains about 50% of its activity. The identified F587A mutant not only has higher specific activity than the WT enzyme, but also can partially escape the inhibitory effect of α2-AP. It is obvious from the figure that the aromatic ring of F587 is located near S741 in the active site and is exposed to the solvent. This residue may be one of the contact residues that provides binding energy when α2-AP "approaches" and tries to bind to μPlm, and the mutation of F587 weakens the kinetics and thermodynamics of the binding interaction. Pharmaceutical composition of recombinant human μPlm expressed by Escherichia coli

[0116] The present application provides a pharmaceutical composition, which includes recombinant human μPlm expressed by Escherichia coli as a thrombolytic agent, or a pharmaceutically acceptable dosage form thereof, or a pharmaceutically acceptable solvate of the compound or dosage form, and includes a pharmaceutically acceptable excipient.

[0117] Pharmaceutical compositions according to the present application can also be prepared in various forms, such as solid, liquid, gas or lyophilized forms, particularly ointments, creams, transdermal patches, gels, powders, tablets, solutions, in the form of aerosols, granules, pills, suspensions, emulsions, capsules, syrups, elixirs, extracts, tinctures or liquid extracts, or in a form particularly suitable for the desired method of administration. Methods for producing drugs known in the present invention may include, for example, conventional mixing, dissolving, granulating, sugaring, grinding, emulsifying, encapsulating, encapsulating or lyophilizing methods. Pharmaceutical compositions comprising immune cells are generally provided in solution as described herein, and preferably include pharmaceutically acceptable buffers.

[0118] In a specific embodiment, the present disclosure provides a pharmaceutical composition or drug for preventing or treating thromboembolism-related diseases. In some embodiments, the pharmaceutical composition includes a modified nucleic acid, a recombinant nucleic acid, a viral vector genome, an expression vector, a host cell, and a pharmaceutically acceptable carrier.

[0119] In some embodiments, the pharmaceutical composition includes a therapeutically effective amount of a vector or a host cell comprising a modified nucleic acid encoding ASPA, which can increase the expression level and / or activity level of ASPA in the cell.

[0120] In some embodiments, the pharmaceutical composition includes a therapeutically effective amount of a vector or host cell including a modified nucleic acid encoding ASPA, wherein the composition further includes a pharmaceutically acceptable carrier, adjuvant, diluent, excipient and / or other pharmaceutical agent. A pharmaceutically acceptable carrier, adjuvant, diluent, excipient or other pharmaceutical agent is biologically or otherwise undesirable, for example, the material is administered to a subject without causing an undesirable biological effect that exceeds the beneficial biological effect of the material. Kit containing recombinant human μPlm expressed in E. coli

[0121] The present application provides a kit, including recombinant human μPlm expressed by Escherichia coli as a thrombolytic agent, or a pharmaceutically acceptable dosage form thereof, or a pharmaceutically acceptable solvate of the compound or dosage form, and including a pharmaceutically acceptable excipient. The kit may also include a buffer. In addition to the above-mentioned components, the kit may also include instructions. These instructions may be present in the kit in a variety of forms, and one or more instructions may be present in the kit. One form of these instructions may be in the form of printed information on a suitable medium or substrate, such as packaging in a medicine box, printing information on one or more pages of the drug instructions, and the like. The description may be present on a computer-readable medium, such as a disk, CD, DVD, etc., for information recording. These instructions may be present on a website, or the website may be deleted via Internet access. Other suitable methods may exist and be included in the kit. In addition, the kit may include a container, which may be an indicative instruction given by a government regulatory agency for the manufacture, use or sale of drugs or biological products, indicating that the government regulatory agency for the manufacture, use or sale of drugs or biological products has approved its use in humans.

[0122] The kit may include a certain number of nano-dispersed preparations in the form of unit doses, such as vials or multiple doses. Therefore, in some embodiments, the kit includes one or more unit doses of nano-dispersed preparations. As used herein, the term "unit dose" refers to a physiological discrete unit that is physiologically suitable as a unit dose for human and animal subjects, and each unit contains an amount sufficient to produce the desired effect, to calculate the predetermined amount of the nano-dispersed preparation of the present invention. The amount of the title preparation unit dose depends on a variety of factors, such as the specific active agent used, the effect to be achieved, and the pharmacodynamics associated with the active agent in the subject. In other embodiments, the kit may include a single dose of the preparation. Application of pharmaceutical composition and kit for treating thromboembolism-related diseases

[0123] The present application provides the use of a pharmaceutical composition for treating thromboembolism-related diseases and the use of a kit for treating thromboembolism-related diseases.

[0124] Any suitable pharmaceutically acceptable carrier or excipient may be used to prepare the pharmaceutical composition according to the present invention.

[0125] The pharmaceutical composition is usually sterile, pyrogen-free and stable under manufacturing and storage conditions. The pharmaceutical composition can be formulated into a solution (e.g., water, saline, glucose solution, buffer solution or other pharmaceutical sterile liquid), a microemulsion, a liposome or other ordered structure suitable for accommodating high product concentrations. In certain embodiments, the pharmaceutical composition comprising a modified nucleic acid, a vector genome comprising a modified nucleic acid, and a host cell of the present invention is prepared in water or a buffered saline solution. The carrier can be a solvent or a dispersion medium containing, for example, water, ethanol, a polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.) and a suitable mixture thereof. For example, by using a coating such as lecithin, by maintaining the desired particle size in the case of dispersion, and by using a surfactant, appropriate fluidity can be maintained. In certain embodiments, it is preferred to include an isotonic agent in the composition, such as a polyol or sodium chloride such as sugar, mannitol, sorbitol. The long-term adsorption of the injectable composition can be achieved by including an agent that delays absorption in the composition, such as, monostearate and gelatin. In some embodiments, the nucleic acids, vectors and / or host cells of the invention can be administered in a controlled release formulation, for example, in a composition that includes a slow-release polymer or other carrier that protects the product from rapid release, including implants and microencapsulated delivery systems.

[0126] In some embodiments, the pharmaceutical composition is a parenteral pharmaceutical composition, including a composition suitable for intravenous injection; in some embodiments, the pharmaceutical composition containing recombinant human μPlm expressed by E. coli is formulated for administration by ICV injection.

[0127] The kit may be provided with packaging materials and one or more components therein. The kit generally includes a label or packaging insert, including a description of the ingredients or instructions for use of the ingredients in vitro, in vivo or ex vivo. A kit refers to a physical structure comprising one or more components of a kit. The packaging material may maintain the ingredients in a sterile manner and may be made of materials commonly used for such purposes (e.g., paper, glass, plastic, foil, ampoules, vials, tubes, etc.). The label or insert may include information identifying one or more ingredients, dosages, and clinical pharmacology of the active ingredients, including mechanism of action, pharmacokinetics, and pharmacodynamics. The label or insert may include information identifying production, batch number, place of production and date, and expiration date. The label or insert may include disease information for which the kit components may be used. The label or insert may include instructions for clinicians or subjects to use one or more kit components in methods, uses, or treatment regimens or treatment regimens. The instructions may include dosages, frequency of duration, and instructions for implementing any method, use, treatment regimen, or prevention or treatment regimen described herein. The label or insert may include information on potential adverse side effects, complications, or reactions, such as warnings to subjects or clinicians, indicating situations where a particular composition is not suitable for use. Method for treating thromboembolism-related diseases using therapeutically effective amounts of pharmaceutical compositions and kits

[0128] The present application provides a method for treating thromboembolism-related diseases caused by various disease conditions such as SARS-CoV2 infection and sepsis, which include ischemic stroke, myocardial infarction, deep vein thrombosis, peripheral arterial occlusion, pulmonary embolism and systemic blood coagulation, wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition and kit, or a pharmaceutically acceptable dosage form thereof, or a pharmaceutically acceptable solvate of the compound or dosage form to a subject suffering from these diseases.

[0129] In some embodiments, the pharmaceutical composition is administered by intravenous injection, catheter-directed local administration, subcutaneous, submuscular and aerosol routes. In animal models, E-μPlm can protect mice from thrombin-induced pulmonary embolism and death without causing fatal bleeding side effects. Table 4 shows that in the mouse MCAO model, E-μPlm can completely rescue mice from fatal ischemic stroke without bleeding side effects, while tPA has poor therapeutic effects and bleeding side effects. The specific steps for conducting animal experiments can be found in US17 / 709403. Animal disease model-1, pulmonary embolism model

[0130] Table 4 shows the results of the mouse pulmonary embolism model, wherein it is shown that the negative control (lanes 1 and 2) was not injected with thrombin and drugs, and both animals survived. The positive control (lanes 3 and 4) was injected with thrombin, but not injected with drugs, and died at 17 minutes and 10 minutes, respectively. In all test cases (lanes 5-10), the E-μPlm drug was injected 5 minutes after the injection of thrombin, and the result was that all animals survived. The results show that the drug E-μPlm can effectively save animals from lethal pulmonary embolism caused by thrombin. Table 4

[0131] Fig. 20 The tissue sections after the experiment are shown. The upper figure (I) shows a lung tissue section, showing that thrombin caused a blood clot (left figure), the control group did not show a blood clot (middle figure), and E-μPlm dissolved the blood clot caused by thrombin (right figure). The lower figure (II) shows a heart tissue section, showing that thrombin caused a pulmonary thrombosis, and the heart was bloodless (left figure). The control group without thrombin showed normal blood in the heart (middle figure), and E-μPlm restored the blood blockage caused by thrombin, and the blood in the heart was normal (right figure). Animal disease model-2, MCAO model

[0132] Table 5 shows that in the mouse MCAO model, the mice in the sham operation group were normal, but the control group showed obvious neurological defects, with defect scores as high as 4.3 points. There were significant differences between the E-μPlm group and the control group, and the neurological deficit score was significantly reduced. The death count showed that there were 6 deaths (37.3%) in the control group, while there was only 1 death in the E-μPlm low-dose group (5 mg / kg). More importantly, there were no deaths in the high-dose group (10 mg / kg). This is obviously consistent with the tPA group: there were 2 deaths in the low-dose group (4 mg / kg) and 3 deaths in the high-dose group. The higher mortality rate in the high-dose tPA group is attributed to the hemorrhagic side effects of tPA. In addition, the infarct volume in the control group was higher (351.3mm 3 ), but both E-μPlm and tPA treatment could significantly reduce infarct volume, among which high-dose μPlm contributed the most. Table 5

[0133] Table 6 shows that μPlm treatment did not lead to an increase in bleeding time, clearly indicating that μPlm treatment is safe. However, tPA treatment greatly increased bleeding time, indicating that tPA is less safe than μPlm. Table 6 discuss

[0134] PAs dominate thrombolytic therapy, but their inherent low efficacy and bleeding side effects are not easy to solve. According to Marder's analysis, the future treatment direction should be direct thrombolysis based on PLM. Marder pointed out that there are two main reasons for choosing PLM instead of PAs. First, PLM is an enzyme that dissolves fibrin, and PLM-based treatments will be more effective and can avoid the problem of Plg depletion in some clinical situations. Second, with the maturity and advancement of CDT, PLM can directly enter the obstructing thrombus, and once it diffuses into the serum, it will be neutralized by α2-AP, which may avoid bleeding side effects.

[0135] Having described some illustrative embodiments of the present disclosure, it will be understood by those skilled in the art that the foregoing is merely illustrative and not restrictive and is presented by way of example only. Many modifications and other illustrative embodiments are within the scope of one of ordinary skill in the art and are considered to be within the scope of the present disclosure. In particular, although many of the examples presented herein involve specific combinations of method behaviors or system elements, it should be understood that these behaviors and those elements may be combined in other ways to achieve the same goals. Actions, elements, and features discussed only in relation to one embodiment are not intended to be excluded from similar effects in other embodiments. In addition, for one or more of the means described, functional limitations are added, for example, in the claimed invention, if any, the means are not intended to be limited to the means disclosed herein for performing the functions described, but are intended to cover within the scope any known or later developed means for performing the functions described.

[0136] The use of ordinal terms such as "first", "second", "third", etc., in the application of modified elements does not by itself imply any priority, precedence, or order of one claimed element over another in the order of a method of execution, but is merely used as a label to distinguish a claimed element having a certain name from another element having the same name (but using an ordinal term) to distinguish the element. Similarly, the use of a), b), etc. or i), ii), etc. does not by itself imply any priority, precedence, or order of steps in the claims. Similarly, the use of these terms in the specification does not by itself imply any required priority, precedence, or order. The use of any such terms also does not indicate the number of elements described (including claimed). The above written description is sufficient to enable a person skilled in the art to practice any invention described in this disclosure. The present disclosure is not limited by the scope of the embodiments provided, which are intended as illustrations of one or more aspects of the described invention, and other functionally equivalent embodiments are within the scope of the described invention. Various modifications of the described invention in addition to those shown and described herein will become apparent to those skilled in the art from the above description and are within the scope of the described invention. The advantages and objects of the described invention are not necessarily included in every embodiment of the described invention.

[0137] The above written description is considered sufficient to enable those skilled in the art to practice the invention. The disclosure is not limited by the scope of the embodiments provided, as the embodiments provided are intended as a single illustration of one aspect of the invention, and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the above description and are within the scope of the attached embodiments. The advantages and objects of the invention are not necessarily included in each embodiment of the invention.

[0138] Throughout this application, various publications are cited. The entire disclosures of these publications are incorporated into this application by reference for all purposes.

Claims

1. A recombinant human microplasmin expressed by Escherichia coli, wherein the surface residues of the catalytic domain in contact with α2-antiplasmin in the human microplasmin are individually changed by alanine scanning mutagenesis method, so that the recombinant human microplasmin expressed by Escherichia coli can dissolve disease-causing thrombi while avoiding the inhibition and bleeding side effects of α2-antiplasmin.

2. The recombinant human microplasmin expressed by E. coli according to claim 1, wherein the surface residues of the catalytic domain of the recombinant human microplasmin expressed by E. coli altered by the alanine scanning mutagenesis method respectively represent loops 1-6, wherein The nucleotide sequence of loop 1 is shown in SEQ ID NO: 3, and the amino acid sequence of loop 1 is shown in SEQ ID NO: 4; The nucleotide sequence of loop 2 is shown in SEQ ID NO: 5, and the amino acid sequence of loop 2 is shown in SEQ ID NO: 6; The nucleotide sequence of loop 3 is shown in SEQ ID NO: 7, and the amino acid sequence of loop 3 is shown in SEQ ID NO: 8; The nucleotide sequence of loop 4 is shown as cagggtgac, and the amino acid sequence of loop 4 is shown as QGD; The nucleotide sequence of loop 5 is shown as SEQ ID NO: 9, and the amino acid sequence of loop 5 is shown as SEQ ID NO: 10; The nucleotide sequence of loop 6 is shown as SEQ ID NO:11, and the amino acid sequence of loop 6 is shown as SEQ ID NO:

12.

3. The recombinant human microplasmin expressed by Escherichia coli according to claim 1, wherein the recombinant human microplasmin expressed by Escherichia coli is marked by the surface residues of the catalytic domain after mutation as follows: Gly739Ala, Arg582Ala, Met585Ala, Lys607Ala, Phe587Ala, Ser608Ala, Arg610Ala, Glu641Ala, Pro642Ala. 4 . The recombinant human microplasmin expressed by E. coli according to claim 1 , wherein the microplasminogen of the recombinant human microplasmin expressed by E. coli is automatically activated at about pH 6.

5.

5. The recombinant human microplasmin expressed by E. coli according to claim 1, wherein the in vivo half-life of the recombinant human microplasmin expressed by E. coli is about 14.3±1.6 minutes to about 28.5±1.1 minutes.

6. The recombinant human microplasmin expressed by E. coli according to claim 1, wherein the recombinant human microplasmin is selected to have biological activity for cleaving and detoxifying pathogenic polypeptides or insoluble fibrin and is resistant to inhibition by α2-antiplasmin.

7. A method for producing the recombinant human microplasmin expressed by Escherichia coli according to claim 1, comprising the following steps: (1) performing alanine scanning mutagenesis on the surface residues of the catalytic domain of the human microplasminogen to obtain the exogenous gene of the recombinant human microplasminogen expressed by the Escherichia coli; (2) inserting the exogenous gene into an E. coli expression system for expression to obtain insoluble inclusion bodies of the recombinant human microplasminogen expressed by the E. coli; (3) renaturing the insoluble inclusion bodies in vitro and purifying the renatured proteins to obtain the mutant of the recombinant human microplasminogen expressed by the Escherichia coli; (4) activating the recombinant human microplasminogen expressed by the Escherichia coli into microplasmin using a plasminogen activator; (5) Selecting mutants that have biological activity in cleaving and detoxifying pathogenic polypeptides or insoluble fibrin and are resistant to inhibition by α2-antiplasmin to obtain the recombinant human microplasmin expressed by Escherichia coli as claimed in claim 1.

8. A pharmaceutical composition comprising the recombinant human microplasmin expressed by Escherichia coli as claimed in claim 1 as a thrombolytic agent, or a pharmaceutically acceptable dosage form thereof, or a pharmaceutically acceptable solvate of the compound or dosage form, and a pharmaceutically acceptable excipient.

9. A kit comprising the recombinant human microplasmin expressed by Escherichia coli as claimed in claim 1 as a thrombolytic agent, or a pharmaceutically acceptable dosage form thereof, or a pharmaceutically acceptable solvate of the compound or dosage form, and a pharmaceutically acceptable excipient.

10. Use of the pharmaceutical composition of claim 8 for treating thromboembolism-related diseases.

11. Use of the kit according to claim 9 for treating thromboembolism-related diseases.

12. A method for treating thromboembolism-related diseases including ischemic stroke, myocardial infarction, deep vein thrombosis, peripheral arterial occlusion, pulmonary embolism and systemic blood coagulation caused by various disease conditions such as SARS-CoV2 infection and sepsis, wherein the method comprises administering a therapeutically effective amount of the pharmaceutical composition of claim 8 or a pharmaceutically acceptable dosage form thereof or a pharmaceutically acceptable solvate of the compound or dosage form to a subject suffering from the above-mentioned disease.

13. A method for treating thromboembolism-related diseases including ischemic stroke, myocardial infarction, deep vein thrombosis, peripheral arterial occlusion, pulmonary embolism and systemic blood coagulation caused by various disease conditions such as SARS-CoV2 infection and sepsis, wherein the method comprises administering a therapeutically effective amount of the kit of claim 9 or a pharmaceutically acceptable dosage form thereof or a pharmaceutically acceptable solvate of the compound or dosage form to a subject suffering from the above-mentioned disease.

14. The method for treating thromboembolism-related diseases according to claim 12, wherein the pharmaceutical composition is administered by intravenous, catheter-guided local administration, subcutaneous, submuscular and aerosol routes.

Citation Information

Cited By

  • Recombinant human plasminogen mutant as well as preparation method and application thereof

    CN120775829A